The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling.
The PTEN conundrum: how to target PTEN-deficient prostate cancer. Journal Reviewer, Cell Death and Disease.Journal Reviewer, Disease Models and Mechanisms.Journal Reviewer, Nature Communications.Journal Editor, British Journal of Cancer.NCRI Cancer Conference - invited speaker.Cardiff Prostate Cancer Patient Support group - invited speaker.Prostate Cancer UK, Spotlight webinar - PDX models - invited speaker (Chair).Prostate Cancer Research, public engagement event - invited speaker.2013 – 2014: Richard Pratt Foundation Prostate Cancer Research Fellowship/Victorian Cancer AgencyĢ015 The Australian Society for Stem Cell Research (ASSCR)Ģ014 Australian and New Zealand Urogenital and Prostate (ANZUP) clinical trials groupĢ010 Australian and Canadian Prostate Cancer Research Alliance (AC-PCRA)Ģ005 European Association for Cancer Research (EACR)Ģ005 British Association for Cancer Research (BACR)Ģ004 Royal Society of Biology (RSB) Academic positionsĢ020 - present: Senior Research Fellow (PI, Group Leader), European Cancer Stem Cell Research Centre, Cardiff University, Wales, UKĢ016 – 2020: Research Fellow, European Cancer Stem Cell Research Centre, Cardiff University, Wales, UKĢ012 – 2016: Senior Research Officer, Peter MacCallum Cancer Centre, Melbourne, AustraliaĢ012 – 2016: Honorary Fellow, University of Melbourne, The Sir Peter MacCallum Department of Oncology, Melbourne, AustraliaĢ008 – 2012: Junior Research Officer, Peter MacCallum Cancer Centre, Melbourne, Australia Speaking engagements.2016 – 2020: Marie Slodowska Curie Actions/Horizon2020/Ser Cymru II Fellowship.2020 - 2026: CRUK Career Development Fellowship.This knowledge is applied to the development of novel and more effective biomarkers and therapeutic approaches for prostate cancer. In 2016, I returned to Cardiff University as a Marie Sklodowska-Curie Actions COFUND research fellow and was awarded a Cancer Research Career Development Fellowship in 2020, enabling me to build my research group investigating the molecular mechanisms that underpin prostate cancer growth and therapeutic resistance. In 2012, I became an honorary fellow of Melbourne University and the inaugural Richard Pratt Foundation Fellow for prostate cancer research. I undertook my PhD at Cardiff University, where I developed several new models of prostate cancer with Prof Alan Clarke, and moved to Australia to commence my post-doctoral training at the Peter MacCallum Cancer Centre in Australia.